Preclinical evidence for luteolin in ulcerative colitis: a meta-analysis and systematic review
Evidence suggests that luteolin (LUT) may offer therapeutic potential in treating ulcerative colitis (UC), though its specific pharmacological mechanisms remain incompletely understood. This meta-analysis aims to assess the pharmacological effects of LUT in UC animal models and investigate its poten...
Saved in:
| Published in | Frontiers in pharmacology Vol. 16; p. 1639644 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
2025
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Evidence suggests that luteolin (LUT) may offer therapeutic potential in treating ulcerative colitis (UC), though its specific pharmacological mechanisms remain incompletely understood. This meta-analysis aims to assess the pharmacological effects of LUT in UC animal models and investigate its potential mechanisms of action.
A comprehensive search of five databases, namely, PubMed, Web of Science, Embase, EBSCO, and ScienceDirect, was conducted to identify studies investigating the effects of LUT on UC. The search, covering data up to March 2025, yielded 19 eligible studies involving a total of 327 animal subjects. The outcomes were analyzed using the standard mean difference with a 95% confidence interval in R (4.3.3) software.
The meta-analysis revealed that LUT significantly ameliorated colon length, reduced the disease activity index, alleviated body weight loss, and decreased histological scores. Further mechanistic analysis indicated that LUT exerts its effects through multiple mechanisms, including the reduction of pro-inflammatory cytokines, elevation of anti-inflammatory cytokines, promotion of tight junction protein expression, and improvement of oxidative stress-related indices. However, LUT appears to have no significant impact on the α-diversity of the intestinal microbiota.
This study suggests that LUT may exert significant therapeutic effects in UC animal models through antioxidant, anti-inflammatory, immunomodulatory, and barrier-protective mechanisms. Further clinical studies and translational research are essential to bridge the gap between animal models and human applications.
https://inplasy.com/inplasy-2025-5-0055/, identifier INPLASY202550055. |
|---|---|
| AbstractList | BackgroundEvidence suggests that luteolin (LUT) may offer therapeutic potential in treating ulcerative colitis (UC), though its specific pharmacological mechanisms remain incompletely understood. This meta-analysis aims to assess the pharmacological effects of LUT in UC animal models and investigate its potential mechanisms of action.MethodsA comprehensive search of five databases, namely, PubMed, Web of Science, Embase, EBSCO, and ScienceDirect, was conducted to identify studies investigating the effects of LUT on UC. The search, covering data up to March 2025, yielded 19 eligible studies involving a total of 327 animal subjects. The outcomes were analyzed using the standard mean difference with a 95% confidence interval in R (4.3.3) software.ResultsThe meta-analysis revealed that LUT significantly ameliorated colon length, reduced the disease activity index, alleviated body weight loss, and decreased histological scores. Further mechanistic analysis indicated that LUT exerts its effects through multiple mechanisms, including the reduction of pro-inflammatory cytokines, elevation of anti-inflammatory cytokines, promotion of tight junction protein expression, and improvement of oxidative stress-related indices. However, LUT appears to have no significant impact on the α-diversity of the intestinal microbiota.ConclusionThis study suggests that LUT may exert significant therapeutic effects in UC animal models through antioxidant, anti-inflammatory, immunomodulatory, and barrier-protective mechanisms. Further clinical studies and translational research are essential to bridge the gap between animal models and human applications.Systematic Review Registrationhttps://inplasy.com/inplasy-2025-5-0055/, identifier INPLASY202550055. Evidence suggests that luteolin (LUT) may offer therapeutic potential in treating ulcerative colitis (UC), though its specific pharmacological mechanisms remain incompletely understood. This meta-analysis aims to assess the pharmacological effects of LUT in UC animal models and investigate its potential mechanisms of action.BackgroundEvidence suggests that luteolin (LUT) may offer therapeutic potential in treating ulcerative colitis (UC), though its specific pharmacological mechanisms remain incompletely understood. This meta-analysis aims to assess the pharmacological effects of LUT in UC animal models and investigate its potential mechanisms of action.A comprehensive search of five databases, namely, PubMed, Web of Science, Embase, EBSCO, and ScienceDirect, was conducted to identify studies investigating the effects of LUT on UC. The search, covering data up to March 2025, yielded 19 eligible studies involving a total of 327 animal subjects. The outcomes were analyzed using the standard mean difference with a 95% confidence interval in R (4.3.3) software.MethodsA comprehensive search of five databases, namely, PubMed, Web of Science, Embase, EBSCO, and ScienceDirect, was conducted to identify studies investigating the effects of LUT on UC. The search, covering data up to March 2025, yielded 19 eligible studies involving a total of 327 animal subjects. The outcomes were analyzed using the standard mean difference with a 95% confidence interval in R (4.3.3) software.The meta-analysis revealed that LUT significantly ameliorated colon length, reduced the disease activity index, alleviated body weight loss, and decreased histological scores. Further mechanistic analysis indicated that LUT exerts its effects through multiple mechanisms, including the reduction of pro-inflammatory cytokines, elevation of anti-inflammatory cytokines, promotion of tight junction protein expression, and improvement of oxidative stress-related indices. However, LUT appears to have no significant impact on the α-diversity of the intestinal microbiota.ResultsThe meta-analysis revealed that LUT significantly ameliorated colon length, reduced the disease activity index, alleviated body weight loss, and decreased histological scores. Further mechanistic analysis indicated that LUT exerts its effects through multiple mechanisms, including the reduction of pro-inflammatory cytokines, elevation of anti-inflammatory cytokines, promotion of tight junction protein expression, and improvement of oxidative stress-related indices. However, LUT appears to have no significant impact on the α-diversity of the intestinal microbiota.This study suggests that LUT may exert significant therapeutic effects in UC animal models through antioxidant, anti-inflammatory, immunomodulatory, and barrier-protective mechanisms. Further clinical studies and translational research are essential to bridge the gap between animal models and human applications.ConclusionThis study suggests that LUT may exert significant therapeutic effects in UC animal models through antioxidant, anti-inflammatory, immunomodulatory, and barrier-protective mechanisms. Further clinical studies and translational research are essential to bridge the gap between animal models and human applications.https://inplasy.com/inplasy-2025-5-0055/, identifier INPLASY202550055.Systematic Review Registrationhttps://inplasy.com/inplasy-2025-5-0055/, identifier INPLASY202550055. Evidence suggests that luteolin (LUT) may offer therapeutic potential in treating ulcerative colitis (UC), though its specific pharmacological mechanisms remain incompletely understood. This meta-analysis aims to assess the pharmacological effects of LUT in UC animal models and investigate its potential mechanisms of action. A comprehensive search of five databases, namely, PubMed, Web of Science, Embase, EBSCO, and ScienceDirect, was conducted to identify studies investigating the effects of LUT on UC. The search, covering data up to March 2025, yielded 19 eligible studies involving a total of 327 animal subjects. The outcomes were analyzed using the standard mean difference with a 95% confidence interval in R (4.3.3) software. The meta-analysis revealed that LUT significantly ameliorated colon length, reduced the disease activity index, alleviated body weight loss, and decreased histological scores. Further mechanistic analysis indicated that LUT exerts its effects through multiple mechanisms, including the reduction of pro-inflammatory cytokines, elevation of anti-inflammatory cytokines, promotion of tight junction protein expression, and improvement of oxidative stress-related indices. However, LUT appears to have no significant impact on the α-diversity of the intestinal microbiota. This study suggests that LUT may exert significant therapeutic effects in UC animal models through antioxidant, anti-inflammatory, immunomodulatory, and barrier-protective mechanisms. Further clinical studies and translational research are essential to bridge the gap between animal models and human applications. https://inplasy.com/inplasy-2025-5-0055/, identifier INPLASY202550055. |
| Author | Guo, Enjia Xv, Yichuan Mo, Jianling Feng, Yiyi Lu, Xingyao |
| AuthorAffiliation | 3 Department of Gastroenterology and Hepatology , Hangzhou Red Cross Hospital , Hangzhou , China 2 Department of Gastroenterology , Longhua Hospital , Shanghai University of Traditional Chinese Medicine , Shanghai , China 1 Department of Traditional Chinese Medicine , Sir Run Run Shaw Hospital , School of Medicine , Zhejiang University , Hangzhou , Zhejiang , China |
| AuthorAffiliation_xml | – name: 3 Department of Gastroenterology and Hepatology , Hangzhou Red Cross Hospital , Hangzhou , China – name: 1 Department of Traditional Chinese Medicine , Sir Run Run Shaw Hospital , School of Medicine , Zhejiang University , Hangzhou , Zhejiang , China – name: 2 Department of Gastroenterology , Longhua Hospital , Shanghai University of Traditional Chinese Medicine , Shanghai , China |
| Author_xml | – sequence: 1 givenname: Yiyi surname: Feng fullname: Feng, Yiyi – sequence: 2 givenname: Xingyao surname: Lu fullname: Lu, Xingyao – sequence: 3 givenname: Enjia surname: Guo fullname: Guo, Enjia – sequence: 4 givenname: Jianling surname: Mo fullname: Mo, Jianling – sequence: 5 givenname: Yichuan surname: Xv fullname: Xv, Yichuan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40808687$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkk9r3DAQxUVJadI0X6CHomMv3sqSLEu9lBL6JxBoD-21YiSNEwXb2kr2hv32tbPbkIgBiZnH7wnmvSYnYxqRkLc12wihzYduewt5wxlvNrUSRkn5gpzVSonK6JqfPHmfkotS7thyhDFCyVfkVDLNtNLtGfnzM6Pv4xg99BR3MeDokXYp036eMC0TutTce8wwxR1Sv_SmWD5SoANOUMEI_b7EQmEMtOzLhMMi9DQvMLx_Q1520Be8ON7n5PfXL78uv1fXP75dXX6-rrwQrax0o4RzwIPqnGqDcFJDDSB8aJlpXdMy7k2npVNGeaU4NK1pJde-YzU3TotzcnXghgR3dpvjAHlvE0T70Ej5xkJevtWjlQYFFwa0cV4G3xjmTMCOawDwAVfWpwNrO7sBg8dxytA_gz6fjPHW3qSdrbmQoqlXwvsjIae_M5bJDrF47HsYMc3Frv6SCaGaRfruqdmjy_8NLQJ-EPicSsnYPUpqZtck2Ick2DUJ9pgE8Q-Hhqjd |
| Cites_doi | 10.1016/j.csbj.2025.05.006 10.1016/j.jconrel.2025.02.036 10.1016/j.autrev.2013.06.004 10.1002/jcp.25575 10.1016/j.bcp.2012.11.016 10.1038/nri.2016.88 10.1136/gutjnl-2019-320022 10.1038/nature12721 10.1007/978-1-0716-1468-6_15 10.1007/s00011-021-01468-9 10.1016/j.phymed.2024.155580 10.1007/s00210-020-01814-4 10.1016/j.intimp.2016.08.020 10.1016/j.biopha.2005.03.005 10.1038/onc.2014.445 10.1016/j.mtbio.2022.100246 10.1016/j.tox.2007.04.012 10.1016/j.intimp.2022.109251 10.1016/S1875-5364(24)60568-6 10.1080/03639045.2023.2175850 10.3390/nu17020203 10.1038/nature10208 10.1016/j.autrev.2021.103017 10.3390/foods13071105 10.1016/j.intimp.2023.110996 10.1038/s41401-021-00781-7 10.1016/S0140-6736(23)00966-2 10.1084/jem.20150318 10.1016/j.chom.2021.11.001 10.1093/bbb/zbaa007 10.1016/j.jep.2018.08.033 10.3390/nu10030288 10.1002/ueg2.12317 10.1016/j.jff.2024.106644 10.1080/19490976.2021.1968257 10.1126/sciadv.adh1037 10.1084/jem.20192195 10.1016/j.bbabio.2012.02.033 10.1016/j.ejphar.2023.176166 10.1016/j.dld.2023.11.015 10.1056/NEJMoa1602773 10.1136/bmj.n71 10.1016/j.taap.2025.117239 10.1001/jama.2023.23814 10.1016/j.jep.2024.119157 10.1016/j.fct.2020.111680 10.1016/j.lfs.2020.119008 10.3748/wjg.v28.i30.4053 10.1016/j.jcmgh.2020.04.004 10.1038/s41467-022-32089-3 10.1016/j.intimp.2024.113544 10.1186/1471-2288-14-43 10.1515/med-2023-0785 10.3390/ijms25063236 10.3389/fmicb.2022.1083884 10.3389/fimmu.2024.1425363 10.3164/jcbn.20-192 10.1021/acs.jcim.0c01227 10.1016/j.jff.2024.106207 10.1016/j.plaphy.2022.05.017 10.3389/fcimb.2025.1557331 |
| ContentType | Journal Article |
| Copyright | Copyright © 2025 Feng, Lu, Guo, Mo and Xv. Copyright © 2025 Feng, Lu, Guo, Mo and Xv. 2025 Feng, Lu, Guo, Mo and Xv |
| Copyright_xml | – notice: Copyright © 2025 Feng, Lu, Guo, Mo and Xv. – notice: Copyright © 2025 Feng, Lu, Guo, Mo and Xv. 2025 Feng, Lu, Guo, Mo and Xv |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fphar.2025.1639644 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Feng et al |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_49e3239a89bc4dc590b9def28aaacde8 PMC12343518 40808687 10_3389_fphar_2025_1639644 |
| Genre | Systematic Review Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M~E O5R O5S OK1 P2P PGMZT RNS RPM IPNFZ M48 NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c3374-8563bba2d6fb67d3b48a1aa3cd7097b5702c9f84b696c662a5797428cf0129b83 |
| IEDL.DBID | M48 |
| ISSN | 1663-9812 |
| IngestDate | Wed Aug 27 01:27:03 EDT 2025 Thu Aug 21 18:25:58 EDT 2025 Thu Aug 14 17:33:06 EDT 2025 Sun Aug 17 02:22:51 EDT 2025 Thu Aug 07 07:30:53 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | luteolin ulcerative colitis animal model systematic review meta analysis |
| Language | English |
| License | Copyright © 2025 Feng, Lu, Guo, Mo and Xv. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3374-8563bba2d6fb67d3b48a1aa3cd7097b5702c9f84b696c662a5797428cf0129b83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Edited by: Ruiwen Zhang, University of Houston, United States These authors have contributed equally to this work Rudra Narayan Subudhi, J.S. University, India Reviewed by: Apurva Jadhav, Bharati Vidyapeeth Deemed University, India |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2025.1639644 |
| PMID | 40808687 |
| PQID | 3239403365 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_49e3239a89bc4dc590b9def28aaacde8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12343518 proquest_miscellaneous_3239403365 pubmed_primary_40808687 crossref_primary_10_3389_fphar_2025_1639644 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-00-00 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – year: 2025 text: 2025-00-00 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in pharmacology |
| PublicationTitleAlternate | Front Pharmacol |
| PublicationYear | 2025 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Tan (B51) 2024; 117 Johansson (B21) 2016; 16 Suga (B49) 2021; 69 López-Cauce (B34) 2022; 13 Keir (B22) 2020; 217 Yang (B59); 17 Vukelić (B53) 2020; 145 Westermann (B54) 2012; 1817 Voelker (B52) 2024; 331 Liu (B33) 2025; 124 Magadán-Corpas (B39) 2024; 25 Fillmann (B15) 2007; 236 Kohli (B23) 2022; 184 Li (B28) 2021; 13 Maloy (B41) 2011; 474 McCord (B44) 2005; 59 Bryan (B8) 2013; 85 Lu (B35) 2025; 15 Pan (B47) 2025; 380 Li (B30) 2016; 40 Li (B31) 2022; 43 Quaglio (B48) 2022; 28 Fan (B13) 2015; 34 Furusawa (B17) 2013; 504 Croft (B10) 2022; 13 Page (B46) 2021; 372 Akiyama (B2) 2015; 12 Tan (B50) 2022; 14 Li (B25) 2021; 269 Liu (B32) 2020; 393 Feagan (B14) 2016; 375 Cao (B9) 2025; 496 Bi (B6) 2024; 13 Ding (B12) 2021; 85 Luo (B37) 2019; 231 Li (B26) 2023; 18 Zhang (B62) 2024; 130 Ma (B38) 2023; 9 Xie (B56) 2022; 112 Nakase (B45) 2022; 21 D’Haens (B11) 2021; 70 Althagafy (B4) 2023; 960 Aparicio-Domingo (B5) 2015; 212 Bolz (B7) 2021; 61 Mancini (B42) 2020; 10 Mansouri (B43) 2025; 144 Xie (B55) 2024; 22 Foppa (B16) 2024; 56 Yang (B60); 339 Magalhães (B40) 2021; 2315 Agrawal (B1) 2022; 10 Li (B29) 2025; 27 Le Berre (B24) 2023; 402 Jeong (B20) 2018; 10 Alexander (B3) 2022; 30 Xv (B58) 2024; 15 Geremia (B18) 2014; 13 Yun (B61) 2017; 232 Xue (B57) 2023; 124 Hooijmans (B19) 2014; 14 Lu (B36) 2023; 49 Li (B27) 2021; 70 |
| References_xml | – volume: 27 start-page: 1850 year: 2025 ident: B29 article-title: New targets for the treatment of ulcerative colitis: gut microbiota and its metabolites publication-title: Comput. Struct. Biotechnol. J. doi: 10.1016/j.csbj.2025.05.006 – volume: 380 start-page: 829 year: 2025 ident: B47 article-title: Chemotaxis-driven hybrid liposomes recover intestinal homeostasis for targeted colitis therapy publication-title: J. Control Release doi: 10.1016/j.jconrel.2025.02.036 – volume: 13 start-page: 3 year: 2014 ident: B18 article-title: Innate and adaptive immunity in inflammatory bowel disease publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2013.06.004 – volume: 232 start-page: 1123 year: 2017 ident: B61 article-title: Endothelial STAT3 activation increases vascular leakage through downregulating tight junction proteins: implications for diabetic retinopathy publication-title: J. Cell Physiol. doi: 10.1002/jcp.25575 – volume: 85 start-page: 705 year: 2013 ident: B8 article-title: The Nrf2 cell defence pathway: keap1-Dependent and -independent mechanisms of regulation publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2012.11.016 – volume: 16 start-page: 639 year: 2016 ident: B21 article-title: Immunological aspects of intestinal mucus and mucins publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2016.88 – volume: 70 start-page: 1396 year: 2021 ident: B11 article-title: 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future publication-title: Gut doi: 10.1136/gutjnl-2019-320022 – volume: 504 start-page: 446 year: 2013 ident: B17 article-title: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells publication-title: Nature doi: 10.1038/nature12721 – volume: 2315 start-page: 263 year: 2021 ident: B40 article-title: Identification of pan-assay INterference compoundS (PAINS) using an MD-Based protocol publication-title: Methods Mol. Biol. doi: 10.1007/978-1-0716-1468-6_15 – volume: 70 start-page: 705 year: 2021 ident: B27 article-title: Luteolin alleviates ulcerative colitis through SHP-1/STAT3 pathway publication-title: Inflamm. Res. doi: 10.1007/s00011-021-01468-9 – volume: 130 start-page: 155580 year: 2024 ident: B62 article-title: Alcohol inducing macrophage M2b polarization in colitis by modulating the TRPV1-MAPK/NF-κB pathways publication-title: Phytomedicine doi: 10.1016/j.phymed.2024.155580 – volume: 393 start-page: 2481 year: 2020 ident: B32 article-title: Flos lonicerae flavonoids attenuate experimental ulcerative colitis in rats via suppression of NF-κB signaling pathway publication-title: Naunyn Schmiedeb. Arch. Pharmacol. doi: 10.1007/s00210-020-01814-4 – volume: 40 start-page: 24 year: 2016 ident: B30 article-title: Luteolin ameliorates dextran sulfate sodium-induced colitis in mice possibly through activation of the Nrf2 signaling pathway publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2016.08.020 – volume: 59 start-page: 139 year: 2005 ident: B44 article-title: SOD, oxidative stress and human pathologies: a brief history and a future vision publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2005.03.005 – volume: 34 start-page: 5252 year: 2015 ident: B13 article-title: SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma publication-title: Oncogene doi: 10.1038/onc.2014.445 – volume: 14 start-page: 100246 year: 2022 ident: B50 article-title: ROS-Responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment publication-title: Mater Today Bio doi: 10.1016/j.mtbio.2022.100246 – volume: 236 start-page: 217 year: 2007 ident: B15 article-title: Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat publication-title: Toxicology doi: 10.1016/j.tox.2007.04.012 – volume: 112 start-page: 109251 year: 2022 ident: B56 article-title: Luteolin alleviates ulcerative colitis by restoring the balance of NCR-ILC3/NCR+ILC3 to repairing impaired intestinal barrier publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2022.109251 – volume: 22 start-page: 991 year: 2024 ident: B55 article-title: Luteolin ameliorates ulcerative colitis in mice via reducing the depletion of NCR+ILC3 through notch signaling pathway publication-title: Chin. J. Nat. Med. doi: 10.1016/S1875-5364(24)60568-6 – volume: 49 start-page: 17 year: 2023 ident: B36 article-title: Enhancement of oral bioavailability and anti-colitis effect of luteolin-loaded polymer micelles with RA (rosmarinic acid)-SS-mPEG as carrier publication-title: Drug Dev. Ind. Pharm. doi: 10.1080/03639045.2023.2175850 – volume: 17 start-page: 203 ident: B59 article-title: Luteolin alleviates ulcerative colitis in mice by modulating gut microbiota and plasma metabolism publication-title: Nutrients doi: 10.3390/nu17020203 – volume: 474 start-page: 298 year: 2011 ident: B41 article-title: Intestinal homeostasis and its breakdown in inflammatory bowel disease publication-title: Nature doi: 10.1038/nature10208 – volume: 21 start-page: 103017 year: 2022 ident: B45 article-title: The influence of cytokines on the complex pathology of ulcerative colitis publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2021.103017 – volume: 13 start-page: 1105 year: 2024 ident: B6 article-title: Fabrication of the rapid self-assembly hydrogels loaded with luteolin: their structural characteristics and protection effect on ulcerative colitis publication-title: Foods doi: 10.3390/foods13071105 – volume: 124 start-page: 110996 year: 2023 ident: B57 article-title: Luteolin ameliorates DSS-induced colitis in mice via suppressing macrophage activation and chemotaxis publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2023.110996 – volume: 43 start-page: 1495 year: 2022 ident: B31 article-title: Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s publication-title: Acta Pharmacol. Sin. doi: 10.1038/s41401-021-00781-7 – volume: 402 start-page: 571 year: 2023 ident: B24 article-title: Ulcerative colitis publication-title: Lancet doi: 10.1016/S0140-6736(23)00966-2 – volume: 212 start-page: 1783 year: 2015 ident: B5 article-title: Type 3 innate lymphoid cells maintain intestinal epithelial stem cells after tissue damage publication-title: J. Exp. Med. doi: 10.1084/jem.20150318 – volume: 30 start-page: 17 year: 2022 ident: B3 article-title: Human gut bacterial metabolism drives Th17 activation and colitis publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.11.001 – volume: 85 start-page: 307 year: 2021 ident: B12 article-title: A natural product phillygenin suppresses osteosarcoma growth and metastasis by regulating the SHP-1/JAK2/STAT3 signaling publication-title: Biosci. Biotechnol. Biochem. doi: 10.1093/bbb/zbaa007 – volume: 231 start-page: 39 year: 2019 ident: B37 article-title: Rhubarb peony decoction ameliorates ulcerative colitis in mice by regulating gut microbiota to restoring Th17/Treg balance publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2018.08.033 – volume: 10 start-page: 288 year: 2018 ident: B20 article-title: l-Glutamine attenuates DSS-induced colitis via induction of MAPK Phosphatase-1 publication-title: Nutrients doi: 10.3390/nu10030288 – volume: 10 start-page: 1113 year: 2022 ident: B1 article-title: Implications of the changing epidemiology of inflammatory bowel disease in a changing world publication-title: United Eur. Gastroenterol. J. doi: 10.1002/ueg2.12317 – volume: 124 start-page: 106644 year: 2025 ident: B33 article-title: Luteolin improves mitochondrial dynamics and function in ulcerative colitis via the miR-195-5p/Notch signalling pathway publication-title: J. Funct. Foods doi: 10.1016/j.jff.2024.106644 – volume: 13 start-page: 1968257 year: 2021 ident: B28 article-title: Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease publication-title: Gut Microbes doi: 10.1080/19490976.2021.1968257 – volume: 9 start-page: eadh1037 year: 2023 ident: B38 article-title: Oxidative stress biomarker triggered multiplexed tool for auxiliary diagnosis of atherosclerosis publication-title: Sci. Adv. doi: 10.1126/sciadv.adh1037 – volume: 217 start-page: e20192195 year: 2020 ident: B22 article-title: The role of IL-22 in intestinal health and disease publication-title: J. Exp. Med. doi: 10.1084/jem.20192195 – volume: 1817 start-page: 1833 year: 2012 ident: B54 article-title: Bioenergetic role of mitochondrial fusion and fission publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbabio.2012.02.033 – volume: 960 start-page: 176166 year: 2023 ident: B4 article-title: Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2023.176166 – volume: 56 start-page: 911 year: 2024 ident: B16 article-title: Microbiota and IBD: current knowledge and future perspectives publication-title: Dig. Liver Dis. doi: 10.1016/j.dld.2023.11.015 – volume: 375 start-page: 1946 year: 2016 ident: B14 article-title: Ustekinumab as induction and maintenance therapy for crohn’s disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1602773 – volume: 372 start-page: n71 year: 2021 ident: B46 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: BMJ doi: 10.1136/bmj.n71 – volume: 496 start-page: 117239 year: 2025 ident: B9 article-title: Formononetin ameliorates DSS-Induced colitis by inhibiting the MAPK/PPAR-γ/NF-κB/ROS signaling pathways publication-title: Toxicol. Appl. Pharmacol. doi: 10.1016/j.taap.2025.117239 – volume: 331 start-page: 716 year: 2024 ident: B52 article-title: What is ulcerative colitis? publication-title: JAMA doi: 10.1001/jama.2023.23814 – volume: 339 start-page: 119157 ident: B60 article-title: Luteolin modulates macrophage phenotypic switching via the AMPK-PPARγ pathway to alleviate ulcerative colitis in mice publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2024.119157 – volume: 145 start-page: 111680 year: 2020 ident: B53 article-title: Luteolin ameliorates experimental colitis in mice through ERK-mediated suppression of inflammation, apoptosis and autophagy publication-title: Food Chem. Toxicol. doi: 10.1016/j.fct.2020.111680 – volume: 12 start-page: 133 year: 2015 ident: B2 article-title: Effect of STAT3 inhibition on the metabolic switch in a highly STAT3-activated lymphoma cell line publication-title: Cancer Genomics Proteomics – volume: 269 start-page: 119008 year: 2021 ident: B25 article-title: Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats publication-title: Life Sci. doi: 10.1016/j.lfs.2020.119008 – volume: 28 start-page: 4053 year: 2022 ident: B48 article-title: Gut microbiota, inflammatory bowel disease and colorectal cancer publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v28.i30.4053 – volume: 10 start-page: 287 year: 2020 ident: B42 article-title: Perturbed mitochondrial dynamics Is a novel feature of colitis that can be targeted to lessen disease publication-title: Cell Mol. Gastroenterol. Hepatol. doi: 10.1016/j.jcmgh.2020.04.004 – volume: 13 start-page: 4344 year: 2022 ident: B10 article-title: Notch, RORC and IL-23 signals cooperate to promote multi-lineage human innate lymphoid cell differentiation publication-title: Nat. Commun. doi: 10.1038/s41467-022-32089-3 – volume: 144 start-page: 113544 year: 2025 ident: B43 article-title: Novel targets for mucosal healing in inflammatory bowel disease therapy publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2024.113544 – volume: 14 start-page: 43 year: 2014 ident: B19 article-title: SYRCLE’s risk of bias tool for animal studies publication-title: BMC Med. Res. Methodol. doi: 10.1186/1471-2288-14-43 – volume: 18 start-page: 20230785 year: 2023 ident: B26 article-title: Luteolin alleviates ulcerative colitis in rats via regulating immune response, oxidative stress, and metabolic profiling publication-title: Open Med. (Wars) doi: 10.1515/med-2023-0785 – volume: 25 start-page: 3236 year: 2024 ident: B39 article-title: Gut microbiota and inflammation modulation in a rat model for ulcerative colitis after the intraperitoneal administration of apigenin, luteolin, and xanthohumol publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms25063236 – volume: 13 start-page: 1083884 year: 2022 ident: B34 article-title: Akkermansia deficiency and mucin depletion are implicated in intestinal barrier dysfunction as earlier event in the development of inflammation in interleukin-10-deficient mice publication-title: Front. Microbiol. doi: 10.3389/fmicb.2022.1083884 – volume: 15 start-page: 1425363 year: 2024 ident: B58 article-title: CXCR1 and CXCR2 are potential neutrophil extracellular trap-related treatment targets in ulcerative colitis: insights from Mendelian randomization, colocalization and transcriptomic analysis publication-title: Front. Immunol. doi: 10.3389/fimmu.2024.1425363 – volume: 69 start-page: 20 year: 2021 ident: B49 article-title: Luteolin suppresses 5-hydroxytryptamine elevation in stimulated RBL-2H3 cells and experimental colitis mice publication-title: J. Clin. Biochem. Nutr. doi: 10.3164/jcbn.20-192 – volume: 61 start-page: 2248 year: 2021 ident: B7 article-title: Toward an understanding of pan-assay interference compounds and promiscuity: a structural perspective on binding modes publication-title: J. Chem. Inf. Model doi: 10.1021/acs.jcim.0c01227 – volume: 117 start-page: 106207 year: 2024 ident: B51 article-title: Centipeda minima (L.) A. Braun and asch. and its representative active compound alleviate DSS-induced ulcerative colitis via inhibition of NLRP3 inflammasome activation and regulation of gut microbiota publication-title: J. Funct. Foods doi: 10.1016/j.jff.2024.106207 – volume: 184 start-page: 56 year: 2022 ident: B23 article-title: Nitric oxide, salicylic acid and oxidative stress: is it a perfect equilateral triangle? publication-title: Plant Physiol. Biochem. doi: 10.1016/j.plaphy.2022.05.017 – volume: 15 start-page: 1557331 year: 2025 ident: B35 article-title: Targeting CD4+ T cells through gut microbiota: therapeutic potential of traditional Chinese medicine in inflammatory bowel disease publication-title: Front. Cell Infect. Microbiol. doi: 10.3389/fcimb.2025.1557331 |
| SSID | ssj0000399364 |
| Score | 2.3677466 |
| SecondaryResourceType | review_article |
| Snippet | Evidence suggests that luteolin (LUT) may offer therapeutic potential in treating ulcerative colitis (UC), though its specific pharmacological mechanisms... BackgroundEvidence suggests that luteolin (LUT) may offer therapeutic potential in treating ulcerative colitis (UC), though its specific pharmacological... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1639644 |
| SubjectTerms | animal model luteolin meta analysis Pharmacology systematic review ulcerative colitis |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYhp15Cm0frNg0qhFwaN47e6q0JDaHQsIcEcqoYPUwKrROyu4f8-4wkJ7tbCr0UfLINlucba76RNd8Qsq-MlSa3b--07lohrW8xz4JWxWSTOdaRyVzg_P1CnV-Jb9fyeqnVV94TVuWBq-GOhE2ccQvG-iBikLbzNqaeGQAIMZUyX4x5S8lUmYNz3FWiVslgFmaP-rsbyPqfTH5CCmKRBqxEoiLY_zeW-edmyaXoc_aSbIy0kX6pw31F1tKwSQ4mVXf64ZBeLsqopof0gE4WitQPW-THBOe1sQSSprGPKEW6StHvUm7bQ_GY_wqp6oDTUHbFTT9ToL_TDFoYpUsoDJEuxJ9pLXzZJldnXy9Pz9uxsUIbONeiNVJx74FF1XulI_fCwDEAD1F3VnupOxZsb4RXVgWlGEiNaQczoc_LVt7wHbI-3A7pDaGdVilhRtt3nRdcMB8wJVMBuEQiYLxoyMcnI7u7qp_hMO_IkLgCicuQuBGShpxkHJ7vzNrX5QR6hBs9wv3LIxry4QlFh99K_gECQ7qdTx0vfeA5V7Ihryuqz48SSJ2NMrohZgXvlbGsXhl-3hQ9bgz-Ir_v2_8x-nfkRbZIXeXZJeuz-3l6j7xn5veKiz8C4AwDzg priority: 102 providerName: Directory of Open Access Journals |
| Title | Preclinical evidence for luteolin in ulcerative colitis: a meta-analysis and systematic review |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40808687 https://www.proquest.com/docview/3239403365 https://pubmed.ncbi.nlm.nih.gov/PMC12343518 https://doaj.org/article/49e3239a89bc4dc590b9def28aaacde8 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VcuGCyjs8KiOhXmhK6reREAJEVSEV7aEr9YRlOw5FKtl2HxL77xk73i6LygUppyRWEn8ezzeO5xuAV1IboVP59kappubC-BrjLFfLNpqoD1VLRUpwPvkqj8f8y5k424JVuaPSgbMbQ7tUT2o8vTj4dbV8jwb_LkWc6G_fdJfnLkl7UnGA7MKgh78Ft9EzqWSoJ4Xu55k5eWPJh9yZfzTd8E9Zxv8m7vn3Fso_fNLRDtwtZJJ8GNC_B1uxvw97o0GNerlPTtfJVbN9skdGa53q5QP4NsLZriRGkliqixIksQRHY0zFfAgei4sQB3VwEvJeudlb4sjPOHe1K4ImxPUtWUtCkyEd5iGMjz6ffjquS7mFOjCmeK2FZN472srOS9Uyz7U7dI6FVjVGeaEaGkynuZdGBimpEwqDEapDlxazvGaPYLuf9PEJkEbJGDHO7ZrGc8apDxioyeCYQHqgPa_g9aqT7eWgqmExGkmQ2AyJTZDYAkkFHxMO13cmRex8YjL9bouBWW4io8w4bXzgbRCm8aaNHdXOudBGXcHLFYoWLSj9FnF9nCxmluXq8IxJUcHjAdXrR3Ek1FpqVYHewHvjXTav9D_Os0o3UgKevvfp_zd9BndSPwwrPs9hez5dxBfIgeZ-N68d7Obh_RtL5Qpw |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preclinical+evidence+for+luteolin+in+ulcerative+colitis%3A+a+meta-analysis+and+systematic+review&rft.jtitle=Frontiers+in+pharmacology&rft.au=Feng%2C+Yiyi&rft.au=Lu%2C+Xingyao&rft.au=Guo%2C+Enjia&rft.au=Mo%2C+Jianling&rft.date=2025&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=16&rft_id=info:doi/10.3389%2Ffphar.2025.1639644&rft.externalDocID=PMC12343518 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |